dMed Biopharmaceutical Co., Ltd.
Edit

dMed Biopharmaceutical Co., Ltd.

http://www.dmedglobal.com/cn
Tags:AssistedAssuranceDataDevelopmentDrugFirmHealthTechManagementMedTechResearch
关于缔脉 缔脉生物医药科技(上海)有限公司是一家立足中国、面向全球的临床合同研究组织(CRO)。员工中有很多是跨国药企的行业精英和中美两国医药监督管理机构的权威专家,借助多年丰富的药物开发经验,从方案设计到申报策略、从运营执行到质量保证,为客户提供更有价值的建议和更可靠的运营管理,为中国及全球生物医药公司和医疗器械公司提供高质量高水准全方位的临床服务,从而提高客户临床研发的效率,缩短研发的周期,提高研发成功的几率。 我们的主营业务包括专家咨询、药政事务与策略、早期开发及临床药理、临床科学与医学事务、临床试验运营、生物统计、临床编程、数据管理、药物安全与警戒、质量保证与临床稽查和系统支持等。 我们的员工覆盖包括上海、北京、武汉、广州、成都、纽约、华盛顿、旧金山和布鲁塞尔等地,全球员工数逾600人,其中60%以上具有硕士或以上学历,五分之一员工有10年以上工作经验。 About dMed dMed is a full-service Clinical Contract Research Organization (CRO), which provides industry solutions to pharmaceutical and medical device companies in China and across the globe. dMed is led by experts in China and the US who originated from leading multinational pharma companies and regulatory agencies. We are uniquely positioned to leverage and integrate China’s new regulatory framework, offer innovative drug development strategies, and help our clients expand globally by tapping into the world’s second largest pharmaceutical market. Our creative and flexible collaboration models will help Chinese and global innovative pharma companies effectively raise efficiency in clinical R&D, scientifically shorten research cycle, and boost success rate. Our business covers consulting, early development & clinical pharmacology, clinical operations, biostatistics & programming, data management, drug safety & pharmacovigilance, clinical science & medical affairs, quality assurance, regulatory affairs and strategy. dMed has set up offices in major cities, including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels, and it employs more than 600 professionals globally, among them 60% holds master above degree and 20% with more than 10 years working experiences.
Location: China, Shanghai
Member count: 501-1000
Total raised: $158M
Founded date: 2016

Investors 3

Funding Rounds 3

DateSeriesAmountInvestorsDeal News
17.12.2020Series C$100M-finsmes.co...
16.10.2019Series B$50M-finsmes.co...
02.12.2016Series A$8M-finsmes.co...

Mentions in press and media 13

DateTitleDescriptionCategoryAuthorSource
12.07.2021In Didi’s ...This is the web version of Ter...--fortune.co...
10.07.2021dMed-Clini...dMed-Clinipace, a Shangai, Chi...China USA-finsmes.co...
07.07.2021dMed-Clini...SHANGHAI and MORRISVILLE, N.C....--en.prnasia...
21.05.2021Recently M...SHANGHAI and MORRISVILLE, N.C....--en.prnasia...
19.12.2020dMed Compl...---qimingvc.c...
17.12.2020Fidelity l...Premium dMed Biopharmaceutica...-Eudora Wan...dealstreet...
17.12.2020dMed Close...dMed, a Shangai, China-based c...China-finsmes.co...
17.12.2020Fidelity l...dMed Biopharmaceutical, a clin...-Eudora Wan...dealstreet...
17.10.2019Legend Cap...Premium Chinese clinical cont...-Liya Sudealstreet...
16.10.2019dMed Secur...dMed and investors signed the ...China-finsmes.co...
Show more